VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including 
Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, 
Placebo-Controlled, Multicenter Clinical Study

Blossey, Alexandra M.; Brückner, a Sina; May, a Marcus; Parzmair, Gerald P.; Sharma, Hitt; Shaligram, Umesh; Grode, Leander; Kaufmann, Stefan H. E.; Netea, Mihai G.; Schindler, Christoph

doi:10.1093/cid/ciac881

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study

MPS-Authors

/persons/resource/persons248446

Kaufmann, Stefan H. E.
Emeritus Group Systems Immunology, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Blossey, A. M., Brückner, a. S., May, a. M., Parzmair, G. P., Sharma, H., Shaligram, U., et al. (2023). VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study. Clinical Infectious Diseases, 76(7), 1304-1310. doi:10.1093/cid/ciac881.

Cite as: https://hdl.handle.net/21.11116/0000-000E-2C1E-1

Abstract

Background:
Bacille Calmette-Guérin (BCG) vaccination can potentially reduce the rate of respiratory infections in vulnerable populations. This study evaluates the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 (COVID-19) in an elderly population.

Methods:
In this phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial, healthy elderly volunteers (N = 2064) were enrolled, randomized (1:1) to receive either VPM1002 or placebo, and followed up remotely for 240 days. The primary outcome was the mean number of days with severe respiratory infections at hospital and/or at home. Secondary endpoints included the incidence of self-reported fever, number of hospital and intensive care unit (ICU) admissions, and number of adverse events.

Results:
A total of 31 participants in the VPM1002 group reported at least 1 day with severe respiratory disease and a mean number of days with severe respiratory disease of 9.39 ± 9.28 while in the placebo group; 38 participants reported a mean of 14.29 ± 16.25 days with severe respiratory disease. The incidence of self-reported fever was lower in the VPM1002 group (odds ratio, 0.46 [95% confidence interval, .28–.74]; P = .001), and consistent trends to fewer hospitalization and ICU admissions due to COVID-19 were observed after VPM1002 vaccination. Local reactions typical for BCG were observed in the VPM1002-vaccinated group, which were mostly of mild intensity.

Conclusions:
Vaccination with VPM1002 is well tolerated and seems to have a prophylactic effect against severe respiratory disease in the elderly.